Renin-Angiotensin System - other agents (sparsentan, atrasentan)
Customize your policy alerts
Sign up for allcareadvantage Policy 134.1 alerts
Get alerted when Policy 134.1 changes without checking for updates manually.
Monitor payer policy activity
Prior authorization policy for coverage of renin-angiotensin system - other agents (Filspari/sparsentan and Vanrafia/atrasentan) for adults with primary IgA nephropathy (IgAN) at risk; governs prescribers, renal specialists, and payer reviewers for AllCare Advantage members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Therapy — Covered when ALL of the following are met
Covered when ALL of the following are met
Approve up to 6 months if all conditions met
Continuation/Renewal Therapy — Renewal covered when ALL of the following are met
Renewal covered when ALL of the following are met
Approve up to 12 months if met
Requests for renin-angiotensin system — other agents (including sparsentan/Vanrafia) where the submitted diagnosis is not primary immunoglobulin A nephropathy (IgAN) at risk are excluded from coverage and should be denied. Documentation must support the FDA‑approved indication of primary IgAN at risk to meet policy criteria.
Use does not meet criteria (and should be denied) when required clinical thresholds or prerequisites are not documented. Examples include: missing laboratory evidence of persistent proteinuria ≥0.5 g/day despite optimal treatment; lack of documentation of failure of or contraindication to initial immunosuppressive therapy with oral systemic glucocorticoids; absence of a renal specialist prescriber; or failure to document contraindication/failure to preferred agents when a non‑preferred agent is requested.
Additional denial scenarios specific to sparsentan include failure to document that an ACE inhibitor or ARB will be discontinued when sparsentan is being initiated in a patient currently receiving one. Renewal requests are denied if the member did not meet initial criteria or if chart documentation does not show clinical efficacy (for example, reduction in proteinuria or stable/improved kidney function compared to baseline).
Clinical & Measurement Thresholds
Prescriber & Prior Authorization Requirements
Prior authorization required; time-limited approvals
Prior authorization is required for these agents. Initial approvals are granted for up to 6 months; renewals may be approved for up to 12 months only if renewal criteria are met (member met initial criteria at baseline and documentation of clinical efficacy is provided).
Step therapy: document prior therapy failure or contraindication
Document failure of or contraindication to initial immunosuppressive therapy with oral systemic glucocorticoids before approval; if a non-preferred agent is requested, document failure or contraindication to preferred agent(s). For sparsentan, if the patient is currently on an ACE inhibitor or ARB, document that the ACE inhibitor or ARB will be discontinued.
- Failure/contraindication to initial oral systemic glucocorticoids required (Criteria #5).
- Non-preferred agent requests require documentation of failure/contraindication to preferred agents (Criteria #8).
- If sparsentan and patient on ACE inhibitor/ARB, documentation that ACE inhibitor/ARB will be discontinued (Criteria #7).
Documentation required with prior authorization
Include documentation that the diagnosis is primary IgA nephropathy (IgAN) at risk, member is ≥18 years old, and that the medication is prescribed by a renal specialist. Provide chart evidence of failure or contraindication to initial oral systemic glucocorticoids and laboratory documentation of persistent proteinuria ≥0.5 g/day despite optimal treatment. For sparsentan, include documentation that an ACE inhibitor or ARB will be discontinued. For non-preferred agents, include prior failure/contraindication to preferred agents.
- Diagnosis consistent with primary IgA nephropathy (IgAN) at risk (Criteria #3).
- Member age ≥18 years (Criteria #2).
- Prescriber specialty: renal specialist (Criteria #4).
- Failure/contraindication to oral systemic glucocorticoids (Criteria #5).
- Laboratory evidence of persistent proteinuria ≥0.5 g/day despite optimal treatment (Criteria #6).
- If sparsentan, documentation that ACE inhibitor or ARB will be discontinued (Criteria #7).
- If requesting a non-preferred agent, documentation of failure/contraindication to preferred agents (Criteria #8).
Triggers that may lead to denial
Denial may be triggered when required criteria or documentation are not met, including member age <18 years, diagnosis not consistent with primary IgAN at risk, medication not prescribed by a renal specialist, lack of documented failure/contraindication to initial oral systemic glucocorticoids, missing lab evidence of persistent proteinuria ≥0.5 g/day despite optimal treatment, failure to discontinue ACE inhibitor/ARB when sparsentan is used, or lack of failure/contraindication documentation for non-preferred agents.
- Member <18 years (Criteria #2 = does not meet criteria).
- Diagnosis not supportive of primary IgAN at risk (Criteria #3 = deny).
- Medication not prescribed by a renal specialist (Criteria #4 = deny).
- No documentation of failure/contraindication to oral systemic glucocorticoids (Criteria #5 = deny).
- No lab documentation of persistent proteinuria ≥0.5 g/day despite optimal treatment (Criteria #6 = deny).
- If sparsentan and ACE inhibitor/ARB not discontinued, deny (Criteria #7 = deny).
- Non-preferred agent without documented failure/contraindication to preferred agents (Criteria #8 = deny).
Key Definitions
Background
Sparsentan (Filspari) is indicated to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk for disease progression. The policy applies to adults aged ≥18 years and requires prior authorization for initiation (approvals up to 6 months) and renewal (approvals up to 12 months) contingent on meeting the coverage criteria and documentation of clinical benefit such as reduced proteinuria or stable/improved kidney function.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.